Akari Therapeutics reports Q2 2026 results; AKTX-101 Phase 1 progress
Akari Therapeutics (AKTX) reports its second quarter 2026 financial results and highlights progress of AKTX-101 toward Phase 1 plus a strategic collaboration for its ADC payload platform.